Drugs Made In America Acquisition (NASDAQ:DMAA – Get Free Report) announced its earnings results on Monday. The company reported $0.05 EPS for the quarter, FiscalAI reports.
Drugs Made In America Acquisition Price Performance
Shares of DMAA remained flat at $10.90 during trading hours on Monday. 35,472 shares of the stock traded hands, compared to its average volume of 72,588. Drugs Made In America Acquisition has a 52 week low of $10.32 and a 52 week high of $10.91. The business’s fifty day simple moving average is $10.86 and its 200-day simple moving average is $10.65.
Hedge Funds Weigh In On Drugs Made In America Acquisition
A hedge fund recently bought a new stake in Drugs Made In America Acquisition stock. First Trust Capital Management L.P. purchased a new stake in shares of Drugs Made In America Acquisition Corp. (NASDAQ:DMAA – Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 786,459 shares of the company’s stock, valued at approximately $8,557,000. First Trust Capital Management L.P. owned about 3.24% of Drugs Made In America Acquisition at the end of the most recent quarter.
Analysts Set New Price Targets
Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Drugs Made In America Acquisition in a research note on Wednesday, August 26th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company currently has an average rating of “Sell”.
View Our Latest Stock Report on DMAA
About Drugs Made In America Acquisition
Drugs Made In America Acquisition Corp. is a special purpose acquisition company formed to pursue a merger, asset acquisition, or similar business combination. It does not operate a pharmaceutical business or manufacture drugs itself. The company’s stated focus was on identifying a business in the pharmaceutical industry, particularly one connected with drug manufacturing in the United States. Its activities were centered on seeking a suitable acquisition or merger candidate.
Featured Stories
- Five stocks we like better than Drugs Made In America Acquisition
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Drugs Made In America Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made In America Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
